BioSpace News Archive

Verismo Therapeutics today announced that a first patient has been dosed in their STAR-101 clinical trial to study the SynKIR-110 product in individuals with advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

Thermo Fisher Scientific to Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023.

VBI Vaccines Inc. announced topline cohort-level unblinded Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179 (VBI-2601), a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha (PEG-IFNα) in chronic hepatitis B virus (HBV) patients compared with PEG-IFNα only treatment.

Viseon Inc. announces the first US clinical use of the First-of-its-Kind 4K Hawkeye™ device for Anterior Lumber Interbody Fusion.

Ventus Therapeutics announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 AM ET.

Nautilus Biotechnology, Inc. today announced the company will be participating in the following investor conferences.

Cytokinetics, Incorporated announced that ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, is open to enrollment.

Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following events in September.

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under its option and license agreement (the “Agreement”) with Lineage Cell Therapeutics, Inc. (“Lineage”).

BioAtla, Inc. today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.